Підписатись
J Dedrick Jordan, MD, PhD
J Dedrick Jordan, MD, PhD
LSU Health Sciences Center Shreveport
Підтверджена електронна адреса в lsuhs.edu
Назва
Посилання
Посилання
Рік
Alirocumab and cardiovascular outcomes after acute coronary syndrome
GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ...
New England Journal of Medicine 379 (22), 2097-2107, 2018
34402018
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
JG Robinson, M Farnier, M Krempf, J Bergeron, G Luc, M Averna, ...
New England Journal of Medicine 372 (16), 1489-1499, 2015
25742015
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ...
New England Journal of Medicine 377 (13), 1228-1239, 2017
21782017
Sotagliflozin in patients with diabetes and recent worsening heart failure
DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ...
New England journal of medicine 384 (2), 117-128, 2021
17282021
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
15512018
Vericiguat in patients with heart failure and reduced ejection fraction
PW Armstrong, B Pieske, KJ Anstrom, J Ezekowitz, AF Hernandez, ...
New England Journal of Medicine 382 (20), 1883-1893, 2020
12532020
Semaglutide and cardiovascular outcomes in obesity without diabetes
AM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, ...
New England Journal of Medicine 389 (24), 2221-2232, 2023
11072023
Sotagliflozin in patients with diabetes and chronic kidney disease
DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ...
New England Journal of Medicine 384 (2), 129-139, 2021
10632021
Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain
X Duan, JH Chang, S Ge, RL Faulkner, JY Kim, Y Kitabatake, X Liu, ...
Cell 130 (6), 1146-1158, 2007
7502007
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ...
New England Journal of Medicine 384 (2), 105-116, 2021
6052021
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial
GG Schwartz, L Bessac, LG Berdan, DL Bhatt, V Bittner, R Diaz, ...
American heart journal 168 (5), 682-689. e1, 2014
5822014
Signaling networks: the origins of cellular multitasking
JD Jordan, EM Landau, R Iyengar
Cell 103 (2), 193-200, 2000
5802000
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
HC Gerstein, N Sattar, J Rosenstock, C Ramasundarahettige, R Pratley, ...
New England journal of medicine 385 (10), 896-907, 2021
5672021
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial
PM Moriarty, PD Thompson, CP Cannon, JR Guyton, J Bergeron, FJ Zieve, ...
Journal of clinical lipidology 9 (6), 758-769, 2015
5642015
Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study
JJ Bazarian, P Biberthaler, RD Welch, LM Lewis, P Barzo, V Bogner-Flatz, ...
The Lancet Neurology 17 (9), 782-789, 2018
5232018
Extended thromboprophylaxis with betrixaban in acutely ill medical patients
AT Cohen, RA Harrington, SZ Goldhaber, RD Hull, BL Wiens, A Gold, ...
New England Journal of Medicine 375 (6), 534-544, 2016
5222016
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY …
CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ...
European heart journal 36 (19), 1186-1194, 2015
5142015
Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial
EC Haley Jr, JLP Thompson, JC Grotta, PD Lyden, TG Hemmen, ...
Stroke 41 (4), 707-711, 2010
3242010
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
2902019
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double …
JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren, WS Jones, ...
The lancet 399 (10333), 1383-1390, 2022
2472022
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20